Submit Manuscript  

Article Details


Gene therapy based on lipid nanoparticles as non-viral vectors for Gliomas treatment

Author(s):

Marcela Tavares Luiz, Larissa Bueno Tofani, Victor Hugo Sousa Araújo, Leonardo Delello Di Filippo, Jonatas Lobato Duarte, Juliana Maldonado Marchetti and Marlus Chorilli*   Pages 1 - 13 ( 13 )

Abstract:


Gliomas are primary brain tumors originating from glial cells, representing 30% of all Central Nervous System (CNS) neoplasia. Among them, the astrocytoma grade IV (glioblastoma multiforme) is the most common presenting an invasive and aggressive profile, with an estimated life expectancy about 15 months after diagnosis even after treatment with radiation, surgical resection, and chemotherapy. This poor prognostic is related to the presence of the blood-brain barrier (BBB) and multidrug resistance mechanisms that avoid the uptake and retention of chemotherapeutics inside the brain. Gene therapy has been a promising strategy to overcome these treatment limitations since it has the ability to modify the defective genetic information in tumor cells, being able to induce cellular apoptosis, and silencing genes responsible for multidrug resistance. Lipid-based nanoparticles, non-viral vectors, have been investigated to deliver genes across the BBB to reach the gliomas cells target. Besides that, its low immunogenicity, easy production, ability in the incorporation of ligands to specific target cells and capacity to carry higher size genes, has become the gene therapy based on non-viral vectors promising glioma treatment. In this context, this review will address the most common non-viral vectors based on lipid-based nanoparticles used for gliomas gene therapy such as liposomes, solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsions.

Keywords:

Brain tumor, blood-brain barrier, glioblastoma multiforme, nanocarriers, nanomedicine, nanotechnology, nanosystems

Affiliation:

School of Pharmaceutical Science of Ribeirao Preto, University of Sao Paulo (USP), Ribeirao Preto, São Paulo,, School of Pharmaceutical Science of Ribeirao Preto, University of Sao Paulo (USP), Ribeirao Preto, São Paulo,, School of Pharmaceutical Science of Sao Paulo State University (UNESP), Araraquara, Sao Paulo,, School of Pharmaceutical Science of Sao Paulo State University (UNESP), Araraquara, Sao Paulo,, School of Pharmaceutical Science of Sao Paulo State University (UNESP), Araraquara, Sao Paulo,, School of Pharmaceutical Science of Ribeirao Preto, University of Sao Paulo (USP), Ribeirao Preto, São Paulo,, School of Pharmaceutical Science of Sao Paulo State University (UNESP), Araraquara, Sao Paulo



Read Full-Text article